Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

ClinicalTrials.gov ID: NCT01010542

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01010542. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A SINGLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF ILV-095 ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH PSORIASIS.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis. Another purpose of the study is to observe how the drug enters the blood and tissues over time, how the body breaks down the drug and whether or not the body will develop an immune reaction (sensitivity) to the drug.

Study identification

NCT ID: NCT01010542
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 39 participants

Conditions and interventions

Conditions

Plaque Psoriasis

Interventions

ILV-095 300 mg in a 4 to 1 ratio Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 1, 2009 (Actual)
Primary completion: May 20, 2011 (Actual)
Completion: May 20, 2011 (Actual)
Last update posted: Jul 3, 2024

2009 – 2011

United States locations

U.S. sites: 7
U.S. states: 5
U.S. cities: 6

Facility	City	State	ZIP	Site status
Cetero Research	Miami Gardens	Florida	33169	—
Miami Research Associates, Inc.	South Miami	Florida	33143	—
MRA Clinical Research	South Miami	Florida	33143	—
Dawes Fretzin Clinical Research Group, LLC	Indianapolis	Indiana	46256	—
Hamzavi Dermatology	Fort Gratiot	Michigan	48059	—
Wake Forest University Health Sciences	Winston-Salem	North Carolina	27104	—
Radiant Research, Inc.	Greer	South Carolina	29651	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01010542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 3, 2024 · Synced Nov 13, 2026